Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
-
REGULATORY MHLW Pursuing Quick Approval of Japan-OK’ed Drugs in Emerging Markets
February 10, 2015
-
ACADEMIA Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April
February 9, 2015
-
ORGANIZATION PhRMA Sets to Make Direct Plea to Finance Minister to Drop Annual Price Cut Plan
February 6, 2015
-
REGULATORY NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
-
BUSINESS Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
-
REGULATORY MHLW Plans Business Suspension Order for Novartis
February 5, 2015
-
REGULATORY R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
-
BUSINESS Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
-
BUSINESS Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
-
BUSINESS Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
-
REGULATORY Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
-
BUSINESS Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports
January 29, 2015
-
BUSINESS PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
-
BUSINESS Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin
January 27, 2015
-
REGULATORY Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
-
REGULATORY Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
-
BUSINESS Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
-
ORGANIZATION Some LDP Members Keen to Tackle Kampo NHI Price Problem
January 21, 2015
-
REGULATORY R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…